相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
A. Deshpande et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor
Michael R. Marit et al.
PLOS ONE (2012)
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos et al.
CANCER DISCOVERY (2012)
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Kamalika Moulick et al.
NATURE CHEMICAL BIOLOGY (2011)
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis
Priya Koppikar et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90
HZ He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice
A Krempler et al.
GENESIS (2004)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)